课题基金 / 基金详情

development of survivin targeted therapy for Adult T-cell leukemia/lymphoma

development of survivin targeted therapy for Adult T-cell leukemia/lymphoma
成人T细胞白血病/淋巴瘤生存素靶向治疗的开发
批准号:
21790324
负责人:
CHE Xiao-Fang
金额:
$2.75万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Young Scientists (B)
财政年份:
2009
资助国家:
日本
项目状态:
已结题
起止时间:
2009 至 2010

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Survivin, an inhibitor of apoptosis protein, is highly expressed in adult T-cell leukemia/lymphoma (ATL), and associated with chemotherapy resistance. Specifically overexpression of survivin has been reported in almost all human malignancies, but not detectable in normal tissues, making survivin targeted therapy an attractive ATL therapy strategy. Survivin is functioning as a homodimer, and interacts with XIAP through N-terminal single globular baculovirus IAP repeat (BIR) domain, protecting XIAP from ubiquitination and increasing its stability that promotes caspase-9 inhibition. In this study, peptides containing the survivin sequence for homodimer formation between Val89 and Lys103 (PTD-(89-103aa)), and the sequence for interacting with XIAP between Lys15 and Met38 (PTD-(15-38aa)), adding the protein transduction domains (PTD) of TAT protein to their amino-terminals for cell permeable, were synthesized. The growth of various leukemia cell lines (ATL cell lines S1T and MT2, leukemia c … More ell lines HL60, NB4, K562, Jurkat) was strongly inhibited after 2 hr incubation with PTD-(15-38aa). However, no growth suppression was observed in the normal cell lines, lung fibroblast cells HEL and Normal Human Umbilical Vein Endothelial Cells HUVEC. Significant cell death of S1T cells was observed after 2hr treatment with PTD-(15-38aa) by Giemsa staining. The proportion of apoptosis fraction estimated by FACS with Annexin V and PI staining in S1T cells was increased in the dose dependent manner. However, Degradation of caspase-9, caspase-3 and PARP was not detected by immunoblotting. Unexpectedly, we found that PTD-(15-38aa) treatment caused a dose dependent increase in the expression of LC3-II and decrease in the expression of p62. These results indicated that autophagy involved in the PTD-(15-38aa)-induced apoptosis in S1T cells. The effect of PTD-(15-38aa) on the interacting of survivin with XIAP was investigated in COS cells co-transfected with Flag-XIAP and Myc-survivin by immunopreciptation. Contrary to expectation, PTD-(15-38aa) dose dependently enhanced the binding of survivin with XIAP. These results suggested that PTD-(15-38aa) strongly inhibited the proliferation of leukemia cells, specifically ATL cells, and caspase activation is not involved in the induction of autophagy- mediated apoptosis by PTD-(15-38aa). Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular basis for the activation of NF-κB by thymidine phosphory lase
胸苷磷酸化酶激活 NF-κB 的分子基础
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [Eda H., Aoki K., 他6名, 田實裕介, Eda H., 田畑祥, Takahiro Fujimoto, Sho Tabata]
通讯作者: Sho Tabata
チミジンホスホリラーゼ発現腫瘍細胞におけるNF-κBの活性化機構
表达胸苷磷酸化酶的肿瘤细胞中 NF-κB 激活机制
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [Eda H., Aoki K., 他6名, 田實裕介, Eda H., 田畑祥]
通讯作者: 田畑祥
DOI: 10.3892/ijo_00000602
发表时间: 2010-05-01
期刊: INTERNATIONAL JOURNAL OF ONCOLOGY
影响因子: 5.2
作者: [Matsushita, Shigeto, Ikeda, Ryuji, Akiyama, Shin-Ichi]
通讯作者: Akiyama, Shin-Ichi
2-Aminophenoxazine-3-one induces cellular apoptosis by causing rapid intracellular acidification and generating reactive oxygen species in human lung adenocarcinoma cells.
2-Aminophenoxazine-3-one 通过引起细胞内快速酸化并在人肺腺癌细胞中产生活性氧来诱导细胞凋亡。
DOI: --
发表时间: 2010
期刊: Int J Oncol. 36
影响因子: --
作者: [Zheng C-L, Che X-F.]
通讯作者: Che X-F.
17
    国内基金
    海外基金
    黑顶卷柏新颖木脂素类靶向分离及PI3K-AKT-Survivin/XIAP通路介导的抗肺癌机制研究
    • 批准号:
      2025JJ50570
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      成飞
    • 依托单位:
    基于PKD1-Hippo-Survivin信号轴探讨PKD1基因突变对附睾囊肿形成的机制研究
    • 批准号:
      82301792
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      方子水
    • 依托单位:
    Survivin维持有丝分裂灾难在肝癌I-125粒子放疗抵抗中的作用机制研究
    Survivin通过降低leptin水平改善能量代谢的作用研究
    • 批准号:
      82300977
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      米日阿依·阿里木江
    • 依托单位: